PRECIGEN, INC. Net Income (Loss) Available to Common Stockholders, Basic
PRECIGEN, INC. (PGEN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$429.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-25
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$23.50M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$325.34M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$19.73M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$23.98M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$429.64M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$126.23M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$95.90M.
- PRECIGEN, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$84.49M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$348.85M derived: sum of 2 quarters · filed 2026-03-25 | -$429.64M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | -$325.34M 10-Q · filed 2025-11-13 | -$406.14M 10-Q · filed 2025-11-13 | ||||
| 2024-12-31 | -$19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$43.70M derived: sum of 2 quarters · filed 2026-03-25 | -$126.23M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | -$23.98M 10-Q · filed 2025-11-13 | -$106.51M 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | -$95.90M 10-K · filed 2026-03-25 | |||||
| 2015-12-31 | -$84.49M 10-K · filed 2016-02-29 | |||||
| 2014-12-31 | $18.83M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$33.89M derived: sum of 2 quarters · filed 2016-02-29 | -$85.94M derived: sum of 3 quarters · filed 2016-02-29 | -$81.82M 10-K · filed 2016-02-29 | ||
| 2014-09-30 | -$52.73M 10-Q · filed 2014-11-13 | -$104.77M derived: sum of 2 quarters · filed 2014-11-13 | -$100.65M 10-Q · filed 2014-11-13 | -$112.86M derived: sum of 4 quarters · filed 2014-11-13 | ||
| 2014-06-30 | -$52.04M 10-Q · filed 2014-08-14 | -$47.93M 10-Q · filed 2014-08-14 | -$60.13M derived: sum of 3 quarters · filed 2014-08-14 | -$51.84M derived: sum of 4 quarters · filed 2014-08-14 | ||
| 2014-03-31 | $4.12M 10-Q · filed 2014-05-09 | -$8.09M derived: sum of 2 quarters · filed 2014-05-09 | $201.00K derived: sum of 3 quarters · filed 2014-05-09 | -$13.70M derived: sum of 4 quarters · filed 2014-08-14 | ||
| 2013-12-31 | -$12.20M 10-K · filed 2014-03-31 | -$3.91M derived: sum of 2 quarters · filed 2014-03-31 | -$17.82M derived: sum of 3 quarters · filed 2014-08-14 | -$57.37M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $8.32M 10-Q · filed 2014-11-13 | $15.44M 10-K · filed 2014-03-31 | -$5.62M derived: sum of 2 quarters · filed 2014-08-14 | -$45.17M 10-Q · filed 2014-11-13 | -$84.97M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | -$13.90M 10-Q · filed 2014-08-14 | -$13.95M 10-Q/A · filed 2013-10-21 | -$56.62M 10-Q · filed 2014-08-14 | -$56.67M 10-Q/A · filed 2013-10-21 | -$93.26M derived: sum of 3 quarters · filed 2015-03-02 | -$119.22M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$42.72M 10-Q · filed 2014-05-09 | -$36.31M 10-K · filed 2014-03-31 | -$79.36M derived: sum of 2 quarters · filed 2015-03-02 | -$105.31M derived: sum of 3 quarters · filed 2015-03-02 | -$127.21M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | -$36.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$62.60M derived: sum of 2 quarters · filed 2015-03-02 | -$84.50M derived: sum of 3 quarters · filed 2015-03-02 | -$103.87M 10-K · filed 2015-03-02 | ||
| 2012-09-30 | -$25.96M 10-Q · filed 2013-11-07 | -$47.86M derived: sum of 2 quarters · filed 2013-11-07 | -$67.23M 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | -$21.90M 10-Q/A · filed 2013-10-21 | -$41.27M 10-Q/A · filed 2013-10-21 | ||||
| 2011-12-31 | -$99.15M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |